Cargando…
Optimizing the Treatment for Advanced Non–Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries: A Review
INTRODUCTION: Osimertinib is the treatment of choice for epidermal growth factor receptor (EGFR)-mutated advanced non–small-cell lung cancer (NSCLC). Because of its high price, many low-income countries, such as Syria, cannot provide osimertinib, which makes it difficult to choose the appropriate tr...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Innovative Healthcare Institute
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448734/ https://www.ncbi.nlm.nih.gov/pubmed/37637235 http://dx.doi.org/10.36401/JIPO-22-29 |